Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Within-patient comparison of serum transthyretin response to Tafamidis versus Acoramidis in ATTR-CM
2026-526526-41-01Phase 4Authorised
- Sponsor
- Medical University of Vienna
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tafamidis and acoramidis in amyloidotic transthyretin cardiomyopathy (ATTR-CM) (2 arms), sponsored by Medical University of Vienna. Primary endpoints: Absolute change in serum transthyretin concentration with tafamidis and Absolute change in serum transthyretin concentration with acoramidis. Planned start Jul 2026; status: authorised.
02
Drugs
tafamidisacoramidis
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on 2026-526526-41-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526526-41-01.